EML4–ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib
EML4–ALK alterations are more common in adenocarcinomas and are rarely found in squamous cell histology. In documented cases, the majority of EML4–ALK translocations are identified in squamous cell histology and occur in patients with no or light smoking history. We report an EML4–ALK4 translocation in a 50-year-old patient with squamous cell carcinoma and an 18 pack-year smoking history. The patient had a near complete response in the CNS to alectinib treatment. Our observation suggests that EML4–ALK genomic testing may be clinically useful in patients with heavy smoking history.
KeywordsSquamous cell lung cancer EML4–ALK translocation Crizotinib Alectinib Smoking Anti-ALK inhibitor treatment
The authors would like to thank the patient and her family.
Compliance with ethical standards
Conflict of interest
All authors declare no conflict of interest.
This article does not contain any studies with human participants performed by any of the authors.
Informed consent was obtained from the patient included in the study.
- 1.Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, Hua S, McNamara P, Mahmood S, Lockerman EL, Fujita N, Nishio M, Harris JL, Shaw AT, Engelman JA (2014) The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 4(6):662–673. https://doi.org/10.1158/2159-8290.CD-13-0846 CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O’Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Janne PA (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368(25):2385–2394. https://doi.org/10.1056/NEJMoa1214886 CrossRefPubMedGoogle Scholar
- 5.NCCN Clinical Practice Guidelines. Non small cell lung cancer. V3.2018. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 21 Mar 2018
- 6.Calio A, Nottegar A, Gilioli E, Bria E, Pilotto S, Peretti U, Kinspergher S, Simionato F, Pedron S, Knuutila S, Tortora G, Eccher A, Santo A, Tondulli L, Inghirami G, Tabbo F, Martignoni G, Chilosi M, Scarpa A, Brunelli M (2014) ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung. J Thor Oncol 9(5):729–732. https://doi.org/10.1097/jto.0000000000000109 CrossRefGoogle Scholar
- 7.Loubiere S, Drezet A, Beau-Faller M, Moro-Sibilot D, Friard S, Wislez M, Blons H, Daniel C, Westeel V, Madroszyk A, Lena H, Merle P, Mazieres J, Zalcman G, Lacave R, Antoine M, Morin F, Missy P, Barlesi F, Auquier P, Cadranel J (2018) Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study. Eur Resp J 51 (3). https://doi.org/10.1183/13993003.01467-2017
- 8.Gutierrez ME, Choi K, Lanman RB, Licitra EJ, Skrzypczak SM, Pe Benito R, Wu T, Arunajadai S, Kaur S, Harper H, Pecora AL, Schultz EV, Goldberg SL (2017) Genomic profiling of advanced non-small cell lung cancer in community settings: gaps and opportunities. Clin Lung Cancer 18(6):651–659. https://doi.org/10.1016/j.cllc.2017.04.004 CrossRefPubMedGoogle Scholar